Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain
Aim: To estimate the cost–effectiveness of cetuximab in combination with radiotherapy compared with radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain. Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time h...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Becaris Publishing Limited
2025-01-01
|
| Series: | Journal of Comparative Effectiveness Research |
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584141803094016 |
|---|---|
| author | Ruth Alvarez Cabellos Jon Cacicedo Susana Redondo Capafons Heidi De los Santos Real Miriam Brines Julian Dario Rubio-Rodriguez Carlos Rubio-Terres |
| author_facet | Ruth Alvarez Cabellos Jon Cacicedo Susana Redondo Capafons Heidi De los Santos Real Miriam Brines Julian Dario Rubio-Rodriguez Carlos Rubio-Terres |
| author_sort | Ruth Alvarez Cabellos |
| collection | DOAJ |
| description | Aim: To estimate the cost–effectiveness of cetuximab in combination with radiotherapy compared with
radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain.
Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time
horizon and quarterly Markov cycles was performed from the perspective of the Spanish National Health
System (NHS). Results: The additional cost and quality-adjusted life-year (QALY) gain per patient receiving
radiotherapy in combination with cetuximab compared with radiotherapy alone was €4356 (95% CI:
€4350–4362) and 0.2380 (95% CI: 0.2370–0.2391) QALY, respectively. The incremental cost per QALY gain
was €18,303 (95% CI: €18,243–18,354) with a probability of cost–effectiveness of 65.4% for a willingness
to pay of €30,000 per QALY gained. Conclusion: According to the results of this analysis, the addition of
cetuximab to radiotherapy would be a cost-effective alternative to radiotherapy alone in the treatment
of locally advanced head and neck cancer in Spain. |
| format | Article |
| id | doaj-art-aad196e01cbb4a65bce3faba1e4be81e |
| institution | Kabale University |
| issn | 2042-6313 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Becaris Publishing Limited |
| record_format | Article |
| series | Journal of Comparative Effectiveness Research |
| spelling | doaj-art-aad196e01cbb4a65bce3faba1e4be81e2025-01-27T15:23:19ZengBecaris Publishing LimitedJournal of Comparative Effectiveness Research2042-63132025-01-0114210.57264/cer-2024-0116Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in SpainRuth Alvarez Cabellos0Jon Cacicedo1Susana Redondo Capafons2Heidi De los Santos Real3Miriam Brines Julian4Dario Rubio-Rodriguez5Carlos Rubio-Terres6Medical Oncology Department, Virgen de la Salud University Hospital, Avda. De Barber, 30, 45005, Toledo, SpainRadiation Oncology Department, Cruces University Hospital/Instituto de Investigacio´ n Biobizkaia, Pza. Cruces, s/n, 48903, Baracaldo, SpainParc Tauli University Hospital, Pharmacy Department, Parc Tauli 1, 08208, Sabadell, SpainMerck, SLU, C/Maria de Molina, 40, 28006, Madrid, Spain, an affiliate of Merck KGaAMerck, SLU, C/Maria de Molina, 40, 28006, Madrid, Spain, an affiliate of Merck KGaAHealth Value, HE Department, C/Virgen de Aranzazu, 21, 28034, Madrid, SpainHealth Value, HE Department, C/Virgen de Aranzazu, 21, 28034, Madrid, SpainAim: To estimate the cost–effectiveness of cetuximab in combination with radiotherapy compared with radiotherapy alone, for the treatment of locally advanced head and neck cancer patients in Spain. Methods: A probabilistic Markov model (second-order Monte Carlo simulation) with a five-year time horizon and quarterly Markov cycles was performed from the perspective of the Spanish National Health System (NHS). Results: The additional cost and quality-adjusted life-year (QALY) gain per patient receiving radiotherapy in combination with cetuximab compared with radiotherapy alone was €4356 (95% CI: €4350–4362) and 0.2380 (95% CI: 0.2370–0.2391) QALY, respectively. The incremental cost per QALY gain was €18,303 (95% CI: €18,243–18,354) with a probability of cost–effectiveness of 65.4% for a willingness to pay of €30,000 per QALY gained. Conclusion: According to the results of this analysis, the addition of cetuximab to radiotherapy would be a cost-effective alternative to radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain.cetuximabcost–effectivenesslocally advanced head and neck cancerradiotherapyspain |
| spellingShingle | Ruth Alvarez Cabellos Jon Cacicedo Susana Redondo Capafons Heidi De los Santos Real Miriam Brines Julian Dario Rubio-Rodriguez Carlos Rubio-Terres Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain Journal of Comparative Effectiveness Research cetuximab cost–effectiveness locally advanced head and neck cancer radiotherapy spain |
| title | Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain |
| title_full | Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain |
| title_fullStr | Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain |
| title_full_unstemmed | Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain |
| title_short | Cost–effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in Spain |
| title_sort | cost effectiveness of cetuximab combined with radiotherapy versus radiotherapy alone in locally advanced head and neck cancer in spain |
| topic | cetuximab cost–effectiveness locally advanced head and neck cancer radiotherapy spain |
| work_keys_str_mv | AT ruthalvarezcabellos costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain AT joncacicedo costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain AT susanaredondocapafons costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain AT heididelossantosreal costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain AT miriambrinesjulian costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain AT dariorubiorodriguez costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain AT carlosrubioterres costeffectivenessofcetuximabcombinedwithradiotherapyversusradiotherapyaloneinlocallyadvancedheadandneckcancerinspain |